#Japan #Tokyo #Employee Health #Abe Yondoud #NMN90000

A Year of NMN90000: Abe Yondoud's Groundbreaking Employee Trial

Abe Yondoud Pharmaceutical, a pioneer in the NMN (Nicotinamide Mononucleotide) supplement industry, has reported remarkable findings from an internal trial called the '90000 Challenge'. This challenge lasted for a year, starting in January 2025, and involved employees taking their high-dose NMN90000 supplement daily. NMN is recognized for its potential in promoting health by serving as a precursor to the coenzyme NAD⁺, which is critical for cellular function and metabolism.

The Purpose of the Trial

The primary aim of this trial was to assess the long-term effects of daily NMN intake on health markers among employees. As NMN was gaining traction in the supplement industry, data on its long-term benefits in real-life scenarios were scarce. Recognizing this gap, Abe Yondoud sought to collect reliable, empirical data on the effects of NMN90000, thereby providing transparent information to the public.

Methodology Overview

• - Duration: January 2025 to December 2025 (12 months)
• - Participants: Voluntary employees aged between 30 and 50
• - Intake: The supplement, NMN90000, was consumed daily at a quantity of 3,000 mg
• - Evaluation Metrics: Weight, muscle strength, functions like standing-up tests (for lower limb strength), and health checkup data were monitored and analyzed, compared across three time points: baseline, six months, and one year.

Key Findings

Weight and Muscle Strength

• - Weight Stability: Participants experienced minimal weight fluctuation throughout the year, with a change rate of less than 1%. This indicates that the NMN intake did not lead to significant weight gain or loss.
• - Muscle Strength: Grip strength assessments showed no significant change. However, participants demonstrated consistent results in standing-up tests from different heights, indicating maintained or improved lower limb muscle strength. Participants demonstrated ability in one-legged standing tests using both 40 cm and 21.5 cm high stools.

Blood Test Analysis

The study also included extensive blood test analyses comparing pre-trial results to outcomes at six and twelve months.

• - Blood Sugar Levels (HbA1c): A downward trend indicating improved glucose metabolism was observed after one year.
• - Liver Function (AST and ALT): Most participants remained within the normal range, and a general decline in these liver function markers was noted.
• - Lipid Metabolism (HDL): Increases in HDL levels (“good” cholesterol) were confirmed.
• - Blood Pressure: Overall, participants exhibited a lowering trend in systolic blood pressure while remaining within normal limits, suggesting cardiovascular benefits from NMN supplementation.

The simultaneous improvements in various health indicators stand out, indicating NMN90000 might play a role in enhancing overall health as one ages.

Expert Commentary

Supervised by Dr. Nozomi Uemura, an expert in molecular genetics and neuroscience, the study's results are promising. Dr. Uemura emphasizes that while no drastic changes in strength were universally observed, the potential improvements in lower limb muscle function and various metabolic indicators suggest NMN90000 could support daily health management.

Future Directions

Abe Yondoud aims to continue scientific research to guide product development in health supplements. The company is committed to exploring the broader implications of NMN and its benefits through ongoing research.

About Abe Yondoud Pharmaceutical

Founded in 1731, Abe Yondoud is at the forefront of NMN innovation, recognized for its contribution to the industry by submitting research data that led to NMN’s acceptance as a food product. Based in Adachi, Tokyo, the company focuses on producing high-quality NMN supplements with a purity of 99.9%.

With their commitment to enhancing human health and beauty through advanced science, Abe Yondoud continues to support consumers in maintaining a vibrant quality of life.